Engineered T-Cells take on tough lymphoma in early trial
NCT ID NCT01815749
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to find the safest dose and watch for side effects in 30 patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T-cells (CD19CAR-CD28-CD3zeta-EGFRt T cells)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma by helping the immune system target cancer cells.
- What could go wrong
- This is an early phase I trial with only 30 participants, so safety and effectiveness are not yet proven. There may be serious side effects from the modified cells or the transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Can a new drug combo shield young hearts from transplant complications?
- Combination therapy aims to outsmart tough lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial